Erik Deichmann Heegaard
Keine laufenden Positionen mehr
Vermögen: - $ am 31.03.2024
Profil
Erik Deichmann Heegaard worked as a Medical Director in Novartis Corp.
He then worked as the Chief Medical Officer-GLP 1 Project in Novo Nordisk A from 2011 to 2014.
Currently, he is working as the Chief Medical Officer in Evaxion Biotech A from 2021 to 2023.
Dr. Deichmann Heegaard completed his undergraduate and doctorate degrees from the University of Copenhagen.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
EVAXION BIOTECH A/S
-.--% | 31.03.2023 | 0 ( -.--% ) | - $ | 31.03.2024 |
Ehemalige bekannte Positionen von Erik Deichmann Heegaard
| Unternehmen | Position | Ende |
|---|---|---|
| EVAXION BIOTECH A/S | Chief Tech/Sci/R&D Officer | 01.03.2023 |
| NOVO NORDISK A/S | Chief Tech/Sci/R&D Officer | 01.01.2014 |
Novartis Corp.
 Novartis Corp. Pharmaceuticals: MajorHealth Technology Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY. | Corporate Officer/Principal | - |
Ausbildung von Erik Deichmann Heegaard
| University of Copenhagen | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| NOVO NORDISK A/S | Health Technology |
| EVAXION BIOTECH A/S | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Novartis Corp.
Novartis Corp. Pharmaceuticals: MajorHealth Technology Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY. | Health Technology |
